Roche presents positive topline CGM accuracy data at the 17th International Conference on Advanced Technologies and Treatments for Diabetes

At the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy, Roche shared recent accuracy data for its new Accu-Chek SmartGuide solution for real-time continuous glucose monitoring (rtCGM)International experts discussed how a novel CGM solution using prediction capabilities can address unmet needs of people with diabetes at the Roche symposiumThe presented study results underlined the accurate and safe performance of the solutionBasel, 7 March, 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented the latest data on its novel solution for continuous glucose monitoring. The solution consists of a CGM sensor and two apps designed to display current glucose values and predictions over 30 minutes and two hours. In addition, it features a risk prediction for nocturnal hypoglycemia. Roche is currently working on obtaining CE mark for the Accu-Chek SmartGuide device and will start to launch the solution in selected European countries soon after the clearance.During the company ’s symposium on the occasion of the 17th ATTD International Conference in Florence, Italy, chaired by Professor Chantal Mathieu, University of Leuven, Belgium and Professor Francesco Giorgino, University of Bari, Italy, recent accuracy and performance data of the new CGM solution were shared. Desp ite the advancements made in diabetes therapy and the increased uptake of technology over recent years, still only 55-60% of people with diabetes reach their th...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news